Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2017, Pages

  Pammi, Mohan ^a   Suresh, Gautham ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOFERRIN; MALTODEXTRIN; PLACEBO; PROBIOTIC AGENT;

ABSENCE OF SIDE EFFECTS; ARTIFICIAL MILK; BREAST FEEDING; CHRONIC LUNG DISEASE; DIET SUPPLEMENTATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENCEPHALOMALACIA; ENTERIC FEEDING; EXTREMELY LOW BIRTH WEIGHT; GESTATIONAL AGE; HOSPITAL DISCHARGE; HUMAN; INFANT; LENGTH OF STAY; LOW DRUG DOSE; MORTALITY; NECROTIZING ENTEROCOLITIS; NEUROLOGIC DISEASE; NEWBORN; NEWBORN SEPSIS; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROLENTAL FIBROPLASIA; REVIEW; RISK REDUCTION; SURVIVOR; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERY LOW BIRTH WEIGHT; BACTERIAL INFECTIONS; CAUSE OF DEATH; CHRONIC DISEASE; ENTEROCOLITIS, NECROTIZING; INFANT, PREMATURE, DISEASES; LACTOBACILLUS RHAMNOSUS; LUNG DISEASES; META ANALYSIS; MYCOSES; NUMBERS NEEDED TO TREAT; ORAL DRUG ADMINISTRATION; RETINOPATHY OF PREMATURITY; SEPSIS;

ADMINISTRATION, ORAL; BACTERIAL INFECTIONS; CAUSE OF DEATH; CHRONIC DISEASE; ENTERAL NUTRITION; ENTEROCOLITIS, NECROTIZING; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LACTOBACILLUS RHAMNOSUS; LACTOFERRIN; LUNG DISEASES; MYCOSES; NUMBERS NEEDED TO TREAT; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOPATHY OF PREMATURITY; SEPSIS;

EID: 85021767712     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007137.pub5     Document Type: Review

References (68)

1. Akin IM, Atasay B, Dogu F, Okulu E, Arsan S, Karatas HD, et al. Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. American Journal of Perinatology 2014;31(12):1111-20. [DOI: 10.1055/s-0034-1371704; PUBMED: 24839144]2919955
2. Barrington KJ, Assaad MA, Janvier A. The Lacuna Trial: a double-blind randomized controlled pilot trial of lactoferrin supplementation in the very preterm infant. Journal of Perinatology 2016;36(8):666-9. [DOI: 10.1038/jp.2016.24; PUBMED: 26938920]5741111
3. Kaur G, Gathwala G. Efficacy of bovine lactoferrin supplementation in preventing late-onset sepsis in low birth weight neonates: a randomized placebo-controlled clinical trial. Journal of Tropical Pediatrics 2015;61(5):370-6. [DOI: 10.1093/tropej/fmv044; PUBMED: 26224129]5741113
4. Manzoni P, Meyer M, Stolfi I, Rinaldi M, Cattani S, Pugni L, et al. Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. Early Human Development 2014;90 Suppl 1:S60-5. [DOI: 10.1016/S0378-3782(14)70020-9; PUBMED: 24709463]2919961
5. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, The Italian Society of Neonatology. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009;302(13):1421-8. [PUBMED: DOI: 10.1001/jama.2009.1403; PubMed: 19809023]]5741114
6. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, et al. Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, The Italian Society of Neonatology. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2012;129(1):116-23. [PUBMED: DOI: 10.1542/peds.2011-0279; PubMed: 22184648]]5741115
7. Ochoa TJ, Zegarra J, Cam L, Llanos R, Pezo A, Cruz K, et al. NEOLACTO Research Group. Randomized controlled trial of lactoferrin for prevention of sepsis in Peruvian neonates less than 2500 g. Pediatric Infectious Disease Journal 2015;34(6):571-6. [DOI: 10.1097/INF.0000000000000593; NCT01264536]2919963
8. Sherman MP, Adamkin DH, Niklas V, Radmacher P, Sherman J, Wertheimer F, et al. Randomized controlled trial of talactoferrin oral solution in preterm infants. Journal of Pediatrics 2016;175:68-73.e3. [DOI: 10.1016/j.jpeds.2016.04.084; 3360.7]2919965
9. King JC Jr, Cummings GE, Guo N, Trivedi L, Readmond BX, Keane V, et al. A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. Journal of Pediatric Gastroenterology and Nutrition 2007;44(2):245-51. [DOI: 10.1097/01.mpg.0000243435.54958.68; PUBMED: 17255839]2919967
10. Meyer MP, Alexander T. Reduced rates of necrotizing enterocolitis following routine supplementation with Lactobacillus GG and lactoferrin: an observational study. Poster Session: Neonatology: Neonatal GI Physiology & NEC: Probiotics, Antibiotics and Microbiome. Pediatric Academic Societies Meeting, May 16, 2016, Baltimore Convention Center. Baltimore, Maryland, 2016. [E-PAS2016:4159.485]5741117
11. Ochoa T, Chea-Woo E, Baiocchi N, Pecho I, Campos M, Prada A, et al. Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children. Journal of Pediatrics 2013;162(2):349-56. [DOI: 10.1016/j.jpeds.2012.07.043; PUBMED: 22939927]2919969
12. ISRCTN71737811. Effect of prebiotic or lactoferrin supplementation in formula on the gut flora of preterm infants. www.controlled-trials.com/ISCRTN71737811 (first received 05 September 2008). [DOI: 10.1186/ISRCTN71737811]2919975
13. NCT01172236. Supplementation with lactoferrin in preterm newborns (lactoprenew). clinicaltrials.gov/show/NCT01172236 (first received 28 July 2010). 2919973
14. NCT02959229. Early versus late lactoferrin in prevention of neonatal sepsis [Systematic randomized, single blinded, placebo-controlled trial of early versus late lactoferrin in prevention of neonatal sepsis]. clinicaltrials.gov/show/NCT02959229 (first received 27 October 2016). 5741119
15. ACTRN12611000247976. Lactoferrin infant feeding trial (LIFT) to prevent sepsis and death in preterm infants [Does lactoferrin improve survival free from morbidity in very low birth weight infants? Lactoferrin Infant Feeding Trial: a randomised controlled trial]. www.anzctr.org.au/ACTRN12611000247976 (first received 03 March 2011). 2919983
16. ISRCTN88261002. Enteral lactoferrin In neonates. www.controlled-trials.com/ISRCTN88261002 (first received 05 June 2013). [DOI: 10.1186/ISRCTN88261002]2919979
17. NCT01525316. Lactoferrin for prevention of sepsis in infants (NEOLACTO). clinicaltrials.gov/show/NCT01525316 (first received 30 January 2012). 2919981
18. NCT01821989. Oral lactoferrin supplementation for prevention of sepsis in preterm neonate. clinicaltrials.gov/show/NCT01821989 (first received 27 March 2013). 2919977
19. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Current Opinion in Infectious Diseases 2006;19(3):290-7. [DOI: 10.1097/01.qco.0000224825.57976.87; PUBMED: 16645492]
20. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD005496.pub4]
21. Artym J, Zimecki M, Kruzel ML. Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. International Immunopharmacology 2004;4(9):1149-57. [DOI: 10.1016/j.intimp.2004.05.002; PUBMED: 15251111]
22. Barboza M, Pinzon J, Wickramasinghe S, Froehlich J, Moeller I, Smilowitz J, et al. Glycosylation of human milk lactoferrin exhibits dynamic changes during early lactation enhancing its role in pathogenic bacteria-host interactions. Molecular Cell Proteomics 2012;11(6):M111.015248. [DOI: 10.1074/mcp.M111.015248; PUBMED: 22261723]
23. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187(1):1-7. [PUBMED: 413500]
24. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. Journal of Applied Bacteriology 1992;73(6):472-9. [PUBMED: 1490908]
25. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. American Journal of Respiratory Cell and Molecular Biology 1997;17(1):3-9. [PUBMED: 9224203]
26. Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I, Polito G, et al. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatric Research 2007;61(4):410-4. [DOI: 10.1203/pdr.0b013e3180332c8d; PUBMED: 17515863]
27. Chen PW, Liu ZS, Kuo TC, Hsieh MC, Li ZW. Prebiotic effects of bovine lactoferrin on specific probiotic bacteria. Biometals 2017;30(2):237-48.
28. Dermyshi E, Wang Y, Yan C, Hong W, Qiu G, Gong X, Zhang T. The "golden age" of probiotics: a systematic review and meta-analysis of randomized and observational studies in preterm infants. Neonatology 2017;112(1):9-23.
29. Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman MP. Lactoferrin protects neonatal rats from gut-related systemic infection. American Journal of Physiology. Gastrointestinal and Liver Physiology 2001;281(5):G1140-50. [PUBMED: 11668022]
30. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cellular and Molecular Life Sciences 2005;62(22):2588-98. [DOI: 10.1007/s00018-005-5373-z; PUBMED: 16261252]
31. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 09 March 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
32. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [DOI: 10.1136/bmj.39489.470347.AD; PUBMED: 18436948]
33. Hayes TG, Falchook GF, Varadhachary GR, Smith DP, Davis LD, Dhingra HM, et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Investigational New Drugs 2006;24(3):233-40. [DOI: 10.1007/s10637-005-3690-6; PUBMED: 16193240]
34. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
35. Iwasa M, Kaito M, Ikoma J, Takeo M, Imoto I, Yamauchi K, et al. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. American Journal of Gastroenterology 2002;97(3):766-7. [DOI: 10.1111/j.1572-0241.2002.05573.x; PUBMED: 11922584]
36. Kuipers ME, de Vries HG, Eikelboom MC, Meijer DK, Swart PJ. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrobial Agents and Chemotherapy 1999;43(11):2635-41. [PUBMED: 10543740]
37. Lawn JE, Wilczynska-Ketende K, Cousens SN. Estimating the causes of 4 million neonatal deaths in the year 2000. International Journal of Epidemiology 2006;35(3):706-18. [DOI: 10.1093/ije/dyl043; PUBMED: 16556647]
38. Legrand D. Overview of lactoferrin as a natural immune modulator. Journal of Pediatrics 2016;173(Suppl):S10-5. [DOI: 10.1016/j.jpeds.2016.02.071]
39. Leitch EC, Willcox MD. Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin. Current Eye Research 1999;19(1):12-9. [PUBMED: 10415452]
40. Levy SB. Antimicrobial resistance: bacteria on the defence. Resistance stems from misguided efforts to try to sterilize our environment. BMJ 1998;317(7159):612-3. [PUBMED: 9727983]
41. Lin PW, Stoll BJ. Necrotizing enterocolitis. Lancet 2006;368(9543):1271-83. [DOI: 10.1016/S0140-6736(06)69525-1; PUBMED: 17027734]
42. Lingappan K, Arunachalam A, Pammi M. Lactoferrin and the newborn: current perspectives. Expert Reviews of Anti-Infective Therapy 2013;11(7):695-707. [DOI: 10.1586/14787210.2013.811927; PUBMED: 23879609]
43. Manzoni P. Clinical benefits of lactoferrin for infants and children. Journal of Pediatrics 2016;173(Suppl):S43-52. [DOI: 10.1016/j.jpeds.2016.02.075; PUBMED: 27234411]
44. Neish AS. Molecular aspects of intestinal epithelial cell-bacterial interactions that determine the development of intestinal inflammation. Inflammatory Bowel Diseases 2004;10(2):159-68. [PUBMED: 15168817]
45. Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK, et al. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infection and Immunity 2001;69(3):1469-76. [DOI: 10.1128/IAI.69.3.1469-1476.2001; PUBMED: 11179314]
46. Ochoa TJ, Sizonenko SV. Lactoferrin and prematurity: a promising milk protein?. Biochemistry and Cell Biology 2017;95(1):22-30. [DOI: 10.1139/bcb-2016-0066]
47. Pierce A, Colavizza D, Benaissa M, Maes P, Tartar A, Montreuil J, et al. Molecular cloning and sequence analysis of bovine lactotransferrin. European Journal of Biochemistry 1991;196(1):177-84. [PUBMED: 2001696]
48. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
49. Schünemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. https://gdt.gradepro.org/app/handbook/handbook.html [Updated October 2013].
50. Speer CP. Inflammatory mechanisms in neonatal chronic lung disease. European Journal of Pediatrics 1999;158(Suppl 1):S18-22. [PUBMED: 10592094]
51. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110(2 Pt 1):285-91. [PUBMED: 12165580]
52. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004;292(19):2357-65. [DOI: 10.1001/jama.292.19.2357; PUBMED: 15547163]
53. Stoll BJ. Infections of the neonatal infant. In: Behrman RE, Kliegman R, Jenson HB editor(s). Nelson's Textbook of Pediatrics. 17th Edition. Philadelphia: Saunders, 2004:623-40.
54. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, et al. National Institute of Child Health and Human Development. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatric Infectious Disease Journal 2005;24(7):635-9. [PUBMED: 15999007]
55. Tanaka K, Ikeda M, Nozaki A, Kato N, Tsuda H, Saito S, et al. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Japanese Journal of Cancer Research 1999;90(4):367-71. [PUBMED: 10363572]
56. Tian H, Maddox IS, Ferguson LR, Shu Q. Influence of bovine lactoferrin on selected probiotic bacteria and intestinal pathogens. Biometals 2010;23(3):593-6.
57. Togawa J, Nagase H, Tanaka K, Inamori M, Umezawa T, Nakajima A, et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. American Journal of Physiology. Gastrointestinal and Liver Physiology 2002;283(1):G187-95. [DOI: 10.1152/ajpgi.00331.2001; PUBMED: 12065306]
58. Tomita M, Wakabayashi H, Yamauchi K, Teraguchi S, Hayasawa H. Bovine lactoferrin and lactoferricin derived from milk: production and applications. Biochemistry and Cell Biology 2002;80(1):109-12. [PUBMED: 11908633]
59. Trumpler U, Straub PW, Rosenmund A. Antibacterial prophylaxis with lactoferrin in neutropenic patients. European Journal of Clinical Microbiology and Infectious Diseases 1989;8(4):310-3. [PUBMED: 2497005]
60. Turin CG, Zea-Vera A, Pezo A, Cruz K, Zegarra J, Bellomo S, et al. NEOLACTO Research Group. Lactoferrin for prevention of neonatal sepsis. Biometals 2014;27(5):1007-16. [DOI: 10.1007/s10534-014-9754-3; PUBMED: 24935001]
61. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cellular and Molecular Life Sciences 2005;62(22):2576-87. [DOI: 10.1007/s00018-005-5372-0; PUBMED: 16261253]
62. Venkatesh M, Pham D, Kong L, Weisman L. Prophylaxis with lactoferrin, a novel antimicrobial agent, enhances survival in a neonatal rat model of co-infection. Advances in Therapy 2007;24(5):941-54. [PUBMED: 18029319]
63. Volpe JJ. Neurology of the Newborn. 3rd Edition. Philadelphia, London: WB Saunders, 1995.
64. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. British Journal of Experimental Pathology 1989;70(6):697-704. [PUBMED: 2690922]
65. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. Lancet 2005;365(9465):1175-88. [DOI: 10.1016/S0140-6736(05)71881-X; PUBMED: 15794973]
66. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD007137.pub2]
67. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD007137.pub3]
68. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD007137.pub4]